NAMA
ARCT icon

Nikko Asset Management Americas’s Arcturus Therapeutics ARCT Stock Holding History

Nikko Asset Management Americas’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Sell
1,960,458
-328,477
-14% -$2.59M 0.17% 80
2026
Q1 		$17.6M Buy
2,288,935
+262,347
+13% +$1.91M 0.25% 67
2025
Q4 		$12.4M Buy
2,026,588
+78,753
+4% +$851K 0.14% 86
2025
Q3 		$35.9M Buy
1,947,835
+117,632
+6% +$1.89M 0.35% 63
2025
Q2 		$23.8M Sell
1,830,203
-95,881
-5% -$1.13M 0.24% 71
2025
Q1 		$20.4M Sell
1,926,084
-138,966
-7% -$2.21M 0.26% 64
2024
Q4 		$34.9M Sell
2,065,050
-250,244
-11% -$4.71M 0.38% 52
2024
Q3 		$53.7M Buy
2,315,294
+752,229
+48% +$16.1M 0.61% 42
2024
Q2 		$38M Buy
1,563,065
+286,546
+22% +$8.69M 0.44% 48
2024
Q1 		$43M Sell
1,276,519
-44,133
-3% -$1.56M 0.43% 52
2023
Q4 		$41.6M Sell
1,320,652
-67,922
-5% -$1.61M 0.4% 50
2023
Q3 		$35.4M Sell
1,388,574
-16,358
-1% -$504K 0.42% 51
2023
Q2 		$40.3M Sell
1,404,932
-15,469
-1% -$421K 0.42% 50
2023
Q1 		$33M Sell
1,420,401
-28,659
-2% -$514K 0.38% 44
2022
Q4 		$24.6M Sell
1,449,060
-10,355
-0.7% -$181K 0.35% 51
2022
Q3 		$21.2M Buy
1,459,415
+23,221
+2% +$390K 0.27% 64
2022
Q2 		$18M Buy
1,436,194
+34,116
+2% +$669K 0.22% 67
2022
Q1 		$37.9M Buy
1,402,078
+44,606
+3% +$1.14M 0.28% 67
2021
Q4 		$47.8M Sell
1,357,472
-1,060
-0.1% -$43.2K 0.25% 71
2021
Q3 		$62.5M Buy
1,358,532
+143,631
+12% +$6.44M 0.27% 70
2021
Q2 		$41.2M Buy
1,214,901
+899,089
+285% +$30.4M 0.16% 82
2021
Q1 		$13M Buy
315,812
+38,126
+14% +$2.27M 0.06% 124
2020
Q4 		$12M Buy
277,686
+146,516
+112% +$9.92M 0.07% 123
2020
Q3 		$5.63M Sell
131,170
-12,317
-9% -$611K 0.05% 133
2020
Q2 		$6.56M Sell
143,487
-111,579
-44% -$3.85M 0.09% 98
2020
Q1 		$3.47M Sell
255,066
-25,482
-9% -$326K 0.06% 113
2019
Q4 		$3.05M Sell
280,548
-17,982
-6% -$188K 0.05% 141
2019
Q3 		$3.07M Buy
298,530
+168,556
+130% +$1.82M 0.05% 139
2019
Q2 		$1.23M Buy
129,974
+65,875
+103% +$483K 0.02% 154
2019
Q1 		$438K Buy
+64,099
New +$328K 0.01% 156

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Nikko Asset Management Americas's ARCT Position: Q2 2026 in Review

Nikko Asset Management Americas reduced its Arcturus Therapeutics (ARCT) stake by 14% in Q2 2026, selling an estimated $2.59M and leaving 1,960,458 shares worth $13.1M. The position accounts for 0.17% of the portfolio, ranked #80.

Nikko Asset Management Americas first reported a position in ARCT in Q1 2019 and has held it in 30 quarters since. The position peaked at $62.5M in Q3 2021. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Nikko Asset Management Americas held 1,960,458 shares of Arcturus Therapeutics worth $13.1M as of Q2 2026.
  • Nikko Asset Management Americas sold 328,477 Arcturus Therapeutics shares in Q2 2026, an estimated $2.59M.
  • Arcturus Therapeutics made up 0.17% of Nikko Asset Management Americas's portfolio in Q2 2026, its #80 holding.
  • Nikko Asset Management Americas first reported a position in Arcturus Therapeutics in Q1 2019 and has held it in 30 quarters since.
  • Nikko Asset Management Americas's Arcturus Therapeutics position peaked at $62.5M in Q3 2021.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Nikko Asset Management Americas's 13F filing for Q2 2026, filed 13 Aug 2026.